LGND
LIGAND PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$317.33
−0.45%Next report
Analyst consensus
- Next report date
- Mar 4, 2027
- EPS estimate
- $3.01
- Revenue estimate
- $95.5M
Latest reported
- Last report date
- Oct 29, 2026
- EPS actual
- $2.67
- EPS estimate
- $2.33
- Revenue actual
- $78.7M
- Revenue estimate
- $82.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +15.5%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $350
- PT range
- $326 – $397
- Analysts
- 6
6 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 29, 2026 | $2.33 | $2.67 | Beat 14.59% | $78.7M |
| Aug 6, 2026 | $1.97 | $2.37 | Beat 20.30% | $63.7M |
| May 7, 2026 | $1.84 | $1.63 | Miss -11.41% | $51.7M |
| Feb 26, 2026 | $1.46 | $2.02 | Beat 38.36% | $59.7M |
| Nov 6, 2025 | $1.97 | $3.09 | Beat 56.85% | $115.5M |
| Aug 7, 2025 | $1.54 | $1.60 | Beat 3.90% | $47.6M |
| May 8, 2025 | $1.30 | $1.33 | Beat 2.31% | $45.3M |
| Feb 27, 2025 | $1.37 | -$1.64 | Miss -219.71% | $42.8M |
| Nov 7, 2024 | $0.75 | -$0.39 | Miss -152.00% | $51.8M |
| Feb 27, 2024 | $0.58 | $1.05 | Beat 81.03% | $28.1M |
| May 4, 2023 | $0.89 | $2.28 | Beat 156.18% | $44.0M |
| Feb 22, 2023 | $1.23 | $1.36 | Beat 10.57% | $50.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 4, 2027